Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 4/20 | 0.58 |
| ▸ | ITK | Q08881 | 1/20 | 0.57 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.54 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914894 | 0.92 | ITK (0.67) | FLT3ITKPDPK1MAPK3MAPK1 | |
| SCHEMBL5951894 | 0.91 | FLT3 (0.57) | FLT3ITKPDPK1MAPK3MAPK1 | |
| SCHEMBL14214565 | 0.90 | FLT3 (0.58) | FLT3ITKPDPK1MAPK3MAPK1 | |
| SCHEMBL5952612 | 0.90 | FLT3 (0.58) | FLT3ITKPDPK1MAPK3MAPK1 | |
| SCHEMBL5952801 | 0.90 | FLT3 (0.58) | FLT3ITKPDPK1MAPK3MAPK1 | |
| SCHEMBL5952535 | 0.90 | MAPT (0.59) | FLT3ITKPDPK1MAPK3MAPK1 | |
| SCHEMBL13375064 | 0.90 | FLT3 (0.61) | FLT3ITKPDPK1MAPK3MAPK1 | |
| SCHEMBL14214581 | 0.89 | FLT3 (0.57) | FLT3ITKPDPK1MAPK3MAPK1 | |
| SCHEMBL13373710 | 0.88 | FLT3 (0.54) | FLT3ITKPDPK1MAPK3MAPK1 | |
| SCHEMBL13373689 | 0.88 | FLT3 (0.56) | FLT3ITKMAPK3MAPK1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | claimed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | claimed |
| US-20050009894-A1 | Benzimidazole derivatives and their use as KDR kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2005-01-13 | — | — | US | claimed |
| EP-1442034-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS KDR PROTEIN KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2004-08-04 | — | — | EP | claimed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | claimed |
| WO-2003035644-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS KDR PROTEIN KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2003-05-01 | — | — | WO | claimed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20050009894-A1 | Benzimidazole derivatives and their use as KDR kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2005-01-13 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-1442034-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS KDR PROTEIN KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003035644-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS KDR PROTEIN KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | FLT3 161/4885ITK 979/4885PDPK1 291/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | FLT3 176/4885ITK 1317/4885PDPK1 216/4885 |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | KDR, MUSK, FLT4 | FLT3 80/4885ITK 417/4885PDPK1 584/4885 |
| US-20050009894-A1 | Benzimidazole derivatives and their use as KDR kinase protein inhibitors | KDR, MUSK, FLT4 | FLT3 84/4885ITK 410/4885PDPK1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.